Leukemia clinical trials in Montana

8 actively recruiting leukemia trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed 2026-08-17

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT05254743). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $2,037,139 for research work on this study.

Who paid

Eli Lilly and Company $2,037,139

Paid for research work on this trial

RICHY AGAJANIAN(oncologist on CancerDrs) $243,858
SALEHA SAJID(oncologist on CancerDrs) $165,169
CHANH HUYNH(oncologist on CancerDrs) $153,966
BRUCE CHESON(oncologist on CancerDrs) $152,368
JENNIFER CULTRERA(oncologist on CancerDrs) $151,740

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Healthcare — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT05254743

Sites in Montana:

St. Vincent Frontier Cancer Center — Billings, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03739814

Sites in Montana:

Saint Patrick Hospital - Community Hospital — Missoula, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317649

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554406

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554393

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Great Falls Clinic — Great Falls, Montana

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Montana:

Massive Bio SYNERGY-AI site — Billings, Montana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17